Tong, X.
McNamara, R. P.
Avendaño, M. J.
Serrano, E. F.
García-Salum, T.
Pardo-Roa, C.
Bertera, H. L. http://orcid.org/0000-0001-7431-6436
Chicz, T. M. http://orcid.org/0000-0002-5204-2507
Levican, J.
Poblete, E.
Salinas, E.
Muñoz, A.
Riquelme, A.
Alter, G. http://orcid.org/0000-0002-7680-9215
Medina, R. A. http://orcid.org/0000-0002-5013-6884
Article History
Received: 22 July 2022
Accepted: 1 June 2023
First Online: 13 July 2023
Competing interests
: The authors declare the following competing interests; Galit Alter is a founder/equity holder in Seroymx Systems and Leyden Labs. G.A. has served as a scientific advisor for Sanofi Vaccines. G.A. has collaborative agreements with GSK, Merck, Abbvie, Sanofi, Medicago, BioNtech, Moderna, BMS, Novavax, SK Biosciences, Gilead, and Sanaria. R.A.M. has served as a scientific advisor for Valneva SE. The remaining authors declare no competing interests.